Literature DB >> 9013879

Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex.

B Miloux1, P Laurent, O Bonnin, J Lupker, D Caput, N Vita, P Ferrara.   

Abstract

The human homologue of the recently cloned murine IL-13 binding protein (IL-13R alpha1) was cloned from a cDNA library derived from the carcinoma cell line CAKI-1. The cloned cDNA encodes a 427 amino acid protein with two consensus patterns characteristic of the hematopoietic cytokine receptor family and a short cytoplasmic tail. The human protein is 74% identical to the murine IL-13R alpha1, and 27% identical to the human IL-13R alpha2. CHO cells expressing recombinant hIL-13R alpha1 specifically bind IL-13 (Kd approximately 4 nM) but not IL-4. Co-expression of the cloned cDNA with that of IL-4R alpha resulted in a receptor complex that displayed high affinity for IL-13 (Kd approximately 30 pM), and that allowed cross-competition of IL-13 and IL-4. Electrophoretic mobility shift assay showed that IL-13 and IL-4 were able to activate Stat6 in cells expressing both IL-4R alpha and IL-13R alpha1, while no activation was observed in cells expressing either one or the other alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013879     DOI: 10.1016/s0014-5793(96)01462-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  48 in total

1.  IL-13Rα2 has a protective role in a mouse model of cutaneous inflammation.

Authors:  Umasundari Sivaprasad; Manoj R Warrier; Aaron M Gibson; Weiguo Chen; Yasuhiro Tabata; Stacey A Bass; Marc E Rothenberg; Gurjit K Khurana Hershey
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

2.  Interleukin-4 (IL-4) and IL-13 signaling pathways do not regulate Borrelia burgdorferi-induced arthritis in mice: IgG1 is not required for host control of tissue spirochetes.

Authors:  M R Potter; N Noben-Trauth; J H Weis; C Teuscher; J J Weis
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  History of interleukin-4.

Authors:  William E Paul
Journal:  Cytokine       Date:  2015-03-23       Impact factor: 3.861

4.  Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency.

Authors:  David B Corry; Kirtee Rishi; John Kanellis; Attila Kiss; Li-zhen Song Lz; Jie Xu; Lili Feng; Zena Werb; Farrah Kheradmand
Journal:  Nat Immunol       Date:  2002-03-11       Impact factor: 25.606

Review 5.  Cytokine responses and epithelial function in the intestinal mucosa.

Authors:  Joseph C Onyiah; Sean P Colgan
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

6.  Resistin-like molecule-α regulates IL-13-induced chemokine production but not allergen-induced airway responses.

Authors:  Ariel Munitz; Eric T Cole; Danielle Karo-Atar; Fred D Finkelman; Marc E Rothenberg
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-12       Impact factor: 6.914

7.  IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice.

Authors:  Weiguo Chen; Umasundari Sivaprasad; Yasuhiro Tabata; Aaron M Gibson; Matthew T Stier; Fred D Finkelman; Gurjit K Khurana Hershey
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

9.  Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells.

Authors:  Yutong Zhao; Donghong He; Jing Zhao; Lixin Wang; Alan R Leff; Ernst Wm Spannhake; Steve Georas; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

Review 10.  Linking GATA-3 and interleukin-13: implications in asthma.

Authors:  Sheikh Rayees; Fayaz Malik; Syed Imran Bukhari; Gurdarshan Singh
Journal:  Inflamm Res       Date:  2013-12-22       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.